Freddy Chrisman, MD
Cardiovascular Disease · Little Rock, ARNPI 1649241258
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 61.5% of it on its own, with 40 other manufacturers making up the rest. 2025 is the largest year on record at $12,670, 6.1 times the $2,072 reported in 2019. Among cardiovascular disease clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 481 payments — averaging $53.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$16K
- Angiodynamics, Inc.$2K
- Novartis$1K
- Shockwave Medical, Inc$1K
- Johnson & Johnson$837
- Boston Scientific$674
- plus $4K from 35 others
Across 23 payments — averaging $11,171 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$257K
What the payments were for
- Consulting fees$11,92546%
- Travel & lodging$3,92515%
- Food & beverage$9,87038%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$11,875
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,017
- Impella$227
- PK Papyrus$140
- Orsiro Mission$140
- FFRct$133
- VenaCure 1470 Pro$131
- AMVUTTRA$121
- Abre$119
- GENERAL - THERAPIES$117
How this compares
$25,771 in reported general payments places this provider in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 448 | $345,005 |
| Repatha SureclickEvolocumab | 125 | $83,258 |
| EntrestoSacubitril/Valsartan | 96 | $82,085 |
| XareltoRivaroxaban | 86 | $79,714 |
| Praluent PenAlirocumab | 54 | $30,192 |
| MultaqDronedarone Hcl | 28 | $23,389 |
| Metoprolol Succinate | 1,010 | $11,394 |
| Valsartan | 376 | $7,709 |
| Atorvastatin Calcium | 516 | $4,747 |
| Prasugrel Hcl | 100 | $4,000 |
| Losartan Potassium | 446 | $3,412 |
| Ranolazine ErRanolazine | 48 | $3,341 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 113 | $2,857 |
| ClopidogrelClopidogrel Bisulfate | 267 | $2,376 |
| Ezetimibe | 106 | $2,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $253 | $345,005448 claims |
| NovartisEntresto | $1,159 | $82,08596 claims |
| Johnson & JohnsonXarelto | $837 | $79,71486 claims |
| Sanofi-aventis U.S. LLCMultaq | $122 | $23,38928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
- Michael HuberLittle Rock$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.